<DOC>
	<DOCNO>NCT02741817</DOCNO>
	<brief_summary>The study go compare two different dos aspirin treatment heart disease combination anticlotting medication ticagrelor . One dose aspirin , 75 milligram ( mg ) day , current standard treatment dose aspirin use treat heart attack angina . The , 20 mg twice day , low standard grow scientific evidence , give ticagrelor , might offer advantage usual dose .</brief_summary>
	<brief_title>WilL LOWer Dose Aspirin More Effective Following ACS ? ( WILLOW - ACS )</brief_title>
	<detailed_description>Aspirin establish role treatment ACS secondary prevention ischaemic heart disease . In landmark trial aspirin ACS , ISIS-2 ( 1988 ) , confer benefit similar magnitude thrombolysis . The addition second antiplatelet agent ( P2Y12 inhibitor ) aspirin know improve outcome NSTE-ACS ( Yusuf , Zhao et al . 2001 ) STEMI ( Chen , Jiang et al . 2005 , Sabatine , Cannon et al . 2005 ) . There 2 major class oral P2Y12 inhibitor : irreversibly bind thienopyridine agent , clopidogrel prasugrel , reversibly-binding drug , cyclo-pentyl triazolopyrimidine ticagrelor . A combination aspirin ticagrelor 90 milligram ( mg ) twice daily least 1 year represent current standard treatment ACS recommend European guideline ( Steg , James et al . 2012 , Roffi , Patrono et al . 2015 ) . Aspirin inhibit cyclo-oxygenase ( COX ) enzymes irreversible acetylation , low dose exhibit relative selectivity COX1 , responsible synthesis thromboxane A2 ( TXA2 ) , pro-thrombotic vasoconstrictive eicosanoid . At high dos , aspirin also able inhibit COX2 , lead reduction release anti-thrombotic vasodilatory compound prostacyclin ( PGI2 ) . Aspirin able inhibit platelet aggregation , therefore , inhibit TXA2 relatively PGI2 . Due irreversible binding , COX inhibit platelet lifespan ( typically 10-12 day ) , without nucleus , regenerate enzyme ( Patrono 1994 ) . It think PGI2 act locally rather systemically , healthy individual , COX1 may responsible majority PGI2 production ( Kirkby , Lundberg et al . 2012 ) . In patient atheromatous disease , however , great COX2 expression diseased vessel wall ( Schonbeck , Sukhova et al . 1999 ) therefore may apply area vulnerable thrombosis . COX2 selective inhibitor associate increase cardiovascular risk appear dose dependent class effect ( Mukherjee , Nissen et al . 2001 , Bhala , Emberson et al . 2013 ) . All antithrombotic drug confer risk bleeding . In addition antiplatelet effect , COX1 inhibition aspirin stomach lead acid-induced inflammation ulceration , result bleed . There evidence low dos aspirin associate low rate gastrointestinal bleeding ( Valkhoff , Sturkenboom et al . 2012 ) include combine P2Y12 inhibitor ( Mehta , Tanguay et al . 2010 ) . In UK , 75 mg od standard maintenance dose aspirin consensus Antithrombotic Trialist Collaborators high dos offer added benefit may increase complication rate use secondary prevention ( 2002 ) . Use specific dose stem original formulation anti-inflammatory dose paediatric use , choose approximate 1 grain formerly use unit . Only 1 study aspirin dose patient ACS DAPT carry included patient clopidogrel rather ticagrelor evaluate aspirin dos low 75 mg ( Mehta , Tanguay et al . 2010 ) . Aspirin ticagrelor superior aspirin clopidogrel prevent ischaemic complication ACS increase rate bleeding complication ( Wallentin , Becker et al . 2009 ) . There evidence benefit ticagrelor clopidogrel diminish patient take high dos aspirin compare low dos ( Mahaffey , Wojdyla et al . 2011 ) . The P2Y12 arachidonic acid pathway appear link . P2Y12 inhibition show reduce TXA2 release platelet ( Armstrong , Leadbeater et al . 2011 ) potentiate antiplatelet effect PGI2 vitro ( Cattaneo Lecchi 2007 ) . Ticagrelor act potent P2Y12 inhibitor clopidogrel ( Storey , Angiolillo et al . 2010 ) therefore may contribute . Ticagrelor pleiotropic effect see clopidogrel , include inhibition erythrocyte adenosine uptake ( Bonello , Laine et al . 2014 ) , preclinical model , reduction infarct size , adenosine COX2 dependent effect inhibit high low dose aspirin ( Nanhwan , Ling et al . 2014 ) . Chronic , acute , ticagrelor treatment may upregulate COX2 expression ( Nanhwan , Ling et al . 2014 ) ticagrelor , clopidogrel , improve post-infarct remodeling ( Ye , Birnbaum et al . 2015 ) anticontractile effect vascular smooth muscle cell expose ADP inhibited high dose , low dose , aspirin ( Grzesk , Kozinski et al . 2013 ) . Additionally , statin , give majority patient ACS , reduce infarct size COX2 dependent mechanism , , effect inhibit aspirin dose-dependent manner ( Birnbaum , Lin et al . 2007 ) . Inhibition COX2 high dose aspirin therefore may reduce benefit . In healthy volunteer study , aspirin dose 75 mg daily provide small additional effect platelet prasugrel ex vivo ( Leadbeater et al 2011 ) similar finding show prasugrel ( Armstrong et al 2011 ) ticagrelor ( Kirkby et al 2011 ) vitro , however clinical significance additional effect know study make patient acute coronary syndrome , platelet activation occur persists acute period ( Ault , Cannon et al . 1999 ) . It suggest ticagrelor monotherapy may fact offer advantage DAPT ( Warner , Armstrong et al . 2010 ) 2 trial include ACS patient early period currently progress ( National Institutes Health 2014 , National Institutes Health 2015 ) . However , give fact aspirin still possess antiplatelet effect presence potent P2Y12 inhibition , total omission may prove optimum strategy high risk patient , particularly give current lack evidence patient rather healthy individual . Aspirin inhibit TXA2 PGI2 vivo dose dependent manner daily dos low 20 mg show significantly inhibit TXA2 release ( Warner , Nylander et al . 2011 ) , whilst similar dos provide minimal PGI2 inhibition significant prolongation bleeding time ( Kallmann , Nieuwenhuis et al . 1987 ) . Aspirin dose less 75mg OD study combination P2Y12 inhibitor . A strategy reduce effect aspirin beneficial COX2 whilst maintain antiplatelet effect presence ticagrelor may therefore low dose current standard . Dosing frequency may also open optimization . Aspirin clear plasma quickly administration effect last lifespan platelet due property irreversible inhibitor ( Patrono 1994 ) . However , significant proportion population high rate platelet turnover therefore reduce duration effect may lead inadequate platelet inhibition . This show case patient ischaemic heart disease frequently problem diabetes mellitus , obesity smoker ( Henry , Vermillet et al . 2011 ) . Twice-daily dosing may offer consistency ( Rocca , Santilli et al . 2012 , Paikin , Hirsh et al . 2015 ) . Again , study combination P2Y12 inhibitor . As ticagrelor take twice daily , would significantly inconvenience patient receive dos aspirin way .</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>For inclusion study , subject fulfill follow criterion : 1 . Provision inform consent prior study specific procedures 2 . Male female age great 18 year 3 . Previous diagnosis acute coronary syndrome great 30 day less 10 month enrollment 4 . Receiving dual antiplatelet therapy aspirin 75 mg daily ticagrelor 90 mg twice daily Subjects enter study follow exclusion criterion fulfil : 1 . Presence indication dual antiplatelet therapy ischaemic heart disease 2 . PCI drug elute bare metal stent ( ) within 30 day randomization 3 . Any history stent implantation leave main coronary artery 4 . Any history stent thrombosis dual antiplatelet therapy 5 . Planned procedure coronary revascularization 6 . Any planned surgery procedure may require suspension discontinuation dual antiplatelet therapy expect occur within 3 month randomisation 7 . Prior intention patient physician discontinue aspirin and/or ticagrelor within study period 8 . Receiving dos aspirin ticagrelor 75 mg daily 90mg twice daily respectively</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>